R&D Grants for Tech Companies in Spain 2026
CDTI will mobilise more than 1,800 million euros in 2026 to drive business R&D and innovation in Spain (source: CDTI, cdti.es). For a tech company — from a startup validating its first prototype to an established SME scaling an artificial intelligence platform — that figure is not a headline: it is a real budget that can be accessed with a well-designed funding strategy. The difference between submitting a project and actually securing funding usually comes down to choosing the right scheme based on the company's maturity and correctly combining grants with tax incentives.
This guide covers the landscape of R&D grants for tech companies in Spain in 2026, focusing on CDTI (Neotec, Misiones and its main lines), aid intensities by company size, and how to combine grants with the tax deduction to maximise the return on every euro invested in innovation.
What R&D grants exist for tech companies in Spain in 2026?
In 2026, the main RDI grants for tech companies are channelled through CDTI, which concentrates its funding across five lines: Misiones, Innterconecta-STEP, Cervera, Neotec and Innoglobal. Neotec targets newly created technology-based companies (up to 70% of the eligible budget, maximum 250,000 euros). Misiones funds larger-scale collaborative R&D projects. There is also a complementary tax instrument — the R&D tax deduction — that is not subject to a call and can be combined with the grant.
The key is understanding that not all forms of support are the same type. CDTI structures its funding by combining grants (non-repayable), partially repayable aid (a portion is repaid interest-free or at a reduced rate) and other instruments. Knowing which part of the support is non-repayable and which part must be reimbursed is essential for planning the project's cash flow.
Key takeaway: Do not pursue every scheme simultaneously. First identify your company's maturity and the type of project; the right scheme almost always follows from there.
Grant, loan and repayable aid: what changes for your cash flow
Before choosing a scheme it is worth distinguishing three public funding mechanisms that are often confused:
- Grant (non-repayable): the company receives the amount and does not repay it provided it meets the project milestones and justification requirements. It is the most sought-after instrument for its direct impact on the balance sheet.
- Loan / partially repayable aid: a portion of the amount must be repaid, usually interest-free or at a subsidised rate and with long grace periods. It improves the cost of capital compared with bank financing but creates a future payment obligation.
- Non-repayable tranche within a mixed aid package: many lines combine a repayable component and a non-repayable one, so the effective cost depends on the proportion between the two.
| Mechanism | Repayable? | Cash-flow impact | Typical example |
|---|---|---|---|
| Non-repayable grant | No | Net positive | Neotec, Misiones grant tranche |
| Partially repayable aid | Yes, partially | Future obligation, reduced cost | CDTI R&D project lines |
| R&D tax deduction | No (reduces tax or is monetised) | Recovery via tax liability or cash refund | Article 35 and 39 of the Spanish CIT Law |
This distinction matters because a cash-constrained startup prioritises pure grants, while an SME with stable cash flow can absorb repayable tranches to undertake larger-budget projects.
CDTI 2026: the backbone of technology funding
CDTI is the primary vehicle for business R&D and innovation funding in Spain. In 2026 it will mobilise more than 1,800 million euros (source: CDTI), distributed across competitive grants, partially repayable aid and innovative public procurement. Its most relevant lines for tech companies are:
- Misiones Ciencia e Innovación: collaborative R&D projects aligned with the country's strategic challenges.
- Innterconecta-STEP: high-technology solutions under a public-private cooperation model, strengthening regional ecosystems.
- Cervera: projects in priority technologies defined by the programme.
- Neotec: new business projects from technology-based companies.
- Innoglobal: R&D projects through international technology cooperation.
Each line has its own aid intensity, minimum project budget and funding mechanism, so the fit with the company's strategy must be analysed on a case-by-case basis.
Neotec 2026: the entry point for technology startups
Neotec is designed specifically for startups and newly created technology-based companies. In the 2026 call, the aid covers up to 70% of the eligible budget, with a maximum of 250,000 euros per beneficiary. The application window runs from 14 April to 14 May 2026 (source: CDTI / BOE-B-2026-10827).
It is important to stress the non-repayable grant nature of Neotec, which makes it one of the most attractive forms of support for early-stage companies that do not yet generate recurring revenue and need to finance technology development without taking on debt.
Seek expert advice before drafting the technical report. In competitive schemes such as Neotec, technical quality and the coherence of the business plan are what separate an award from a rejection. Speak to an expert before investing hours in a proposal.
Misiones Ciencia e Innovación 2026: larger-scale collaborative projects
Misiones targets larger-scale R&D projects, typically run by a consortium. The 2026 call has a budget of 60 million euros and applies differentiated maximum aid intensities by company size:
| Company size | Maximum aid intensity |
|---|---|
| Small enterprise | 80% |
| Medium enterprise | 75% |
| Large enterprise | 65% |
These intensities reward SMEs, in line with the objective of strengthening the innovation ecosystem. For a small or medium-sized tech company, participating in a Misiones consortium allows it to undertake an ambitious project while sharing risk and knowledge with other organisations.
How to choose a scheme based on my company's maturity?
The choice of scheme depends primarily on the company's maturity and risk profile. A technology-based startup less than three years old fits naturally into Neotec, given its focus on young companies and its grant nature. An established SME with consortium capacity fits better into Misiones or Innterconecta-STEP, where budgets and aid intensities are higher.
Here is a reference framework for matching each profile to a scheme:
| Company profile | Recommended scheme | Why it fits |
|---|---|---|
| Tech startup (<3 years) | Neotec | Non-repayable grant, focus on young companies |
| Established SME (solo) | Cervera / Innterconecta-STEP | Individual or cooperative R&D projects |
| SME or large company (consortium) | Misiones | Large-scale collaborative projects |
| Company with international cooperation | Innoglobal | R&D through international technology cooperation |
Two practical questions must also be answered: what aid intensity do I need for the project to be viable, and can I absorb a repayable tranche or do I need a pure grant? Answering these questions with data — not intuition — prevents applying to the wrong scheme.
Combining grant and tax deduction: the double leverage
Grants are only one piece of the puzzle. The other major innovation incentive is the R&D tax deduction, regulated in Article 35 of Spanish Corporate Income Tax Law 27/2014 (source: Agencia Tributaria). The two routes are compatible and, when well combined, multiply the return on investment in innovation.
The deduction rates are as follows:
| Item | Deduction rate |
|---|---|
| R&D expenditure (general) | 25% |
| Excess over the two-year average | 42% |
| Additional for researchers dedicated exclusively to R&D | +17% |
| Additional for fixed-asset investment assigned to R&D | +8% |
| Technological Innovation (TI) | 12% |
Furthermore, Article 39.2 of the Spanish Corporate Income Tax Law, Ley 27/2014, allows the monetisation of the deduction: applying it without a tax-liability ceiling with a 20% discount (or requesting a cash refund) subject to certain requirements relating to headcount maintenance, reinvestment and a binding report. For a tech company with little or no tax liability to pay — typical in growth phases — monetisation converts a theoretical tax credit into real liquidity.
Added to this is the 40% rebate on employer social security contributions for common contingencies of research staff dedicated exclusively to R&D and innovation activities (Royal Decree 475/2014). It is compatible with the tax deduction under the terms of that same Royal Decree: directly for SMEs holding the "PYME Innovadora" seal or classified as EBT, and via a binding report for all other companies.
The most costly mistake is forgoing the deduction because a grant has been received. Grant and deduction accumulate; what changes is the calculation base. Planning this from the outset of the project — not at year-end close — is what ensures the maximum benefit.
The binding reasoned report (IMV): legal certainty
To secure the fiscal classification of the project it is advisable to obtain a Binding Reasoned Report (Informe Motivado Vinculante), issued by a certifying body accredited by ENAC. This report is binding on the Agencia Tributaria with respect to the fiscal classification of the project (R&D or Technological Innovation), which dramatically reduces the risk of a subsequent tax adjustment. It is the difference between applying a deduction "in hope" and applying it with legal certainty.
Expert guidance makes the difference
Designing the optimal strategy — choosing the right scheme, calculating aid intensities, deciding between a grant and a repayable tranche, and combining everything with the tax deduction and the social security rebate — requires specific experience in innovation funding. A misfit can leave a sound project unfunded, and a poorly classified deduction can end in a tax inspection.
At Technova we collaborate with Tecnocim Innova, a consultancy specialised in R&D and innovation grants, to support our clients throughout the full innovation funding cycle. With more than 30 years of experience and endorsed by European Union funds, the Ministry of Industry and Tourism and the Escuela de Organización Industrial (EOI), their team covers strategic consultancy, R&D grants, tax deductions (recovering up to 42% of the investment in innovation), R&D social security rebates (up to 40%) and M&A and industrial transfer operations. Their approach connects public funding with business strategy under a clear principle: strategy with impact, innovation with value.
If your tech company is developing a product, that innovation is likely eligible. At Technova we help structure the technology layer of your data and AI projects, so that the technical documentation supports both the grant application and the classification of the tax deduction.
Frequently Asked Questions
Does a CDTI grant have to be repaid?
It depends on the instrument. Non-repayable grants, such as Neotec, do not have to be repaid provided the milestones and justification requirements are met. Other CDTI lines are partially repayable aid: a portion must be repaid, usually interest-free or at a reduced rate and with long grace periods. Before applying it is worth verifying what percentage is a grant and what percentage is a loan.
Can I apply for Neotec if my company is more than three years old?
Neotec is aimed at small, newly created technology-based companies. If your company exceeds the required age, the natural fit is usually another CDTI line such as Cervera, Innterconecta-STEP or Misiones. A prior eligibility analysis avoids applying to a scheme that will reject the application on formal requirements.
Can the CDTI grant and the R&D tax deduction be combined?
Yes. The grant and the R&D tax deduction are compatible. What changes is the deduction's calculation base, since the subsidised amount receives specific treatment. That is why it is advisable to plan both routes from the outset of the project rather than at year-end close.
What aid intensity does an SME receive under Misiones 2026?
Under the 2026 Misiones call, the maximum aid intensity is 80% for small enterprises, 75% for medium enterprises and 65% for large enterprises. These intensities reward SMEs in line with the objective of strengthening the innovation ecosystem. The overall budget of the call is 60 million euros.
What is the binding reasoned report and why does it matter?
It is a report issued by a certifying body accredited by ENAC that classifies the project as R&D or Technological Innovation. Its binding nature vis-à-vis the Agencia Tributaria provides legal certainty for the application of the tax deduction, reducing the risk of a subsequent tax adjustment.
Is the social security rebate compatible with the R&D tax deduction?
Yes, under the terms of Royal Decree 475/2014. The 40% rebate on employer contributions for common contingencies of research staff dedicated exclusively to R&D is compatible with the tax deduction: directly for SMEs holding the "PYME Innovadora" seal or classified as EBT, and via a binding report for all other companies.
Conclusion
The landscape of R&D grants for tech companies in Spain in 2026 is exceptionally favourable: more than 1,800 million euros mobilised by CDTI, a Neotec call with up to 70% non-repayable for startups, intensities of up to 80% under Misiones for small enterprises, and a tax deduction system that allows recovery of up to 42% of the investment in innovation. The opportunity exists; what makes the difference is execution.
Choosing the right scheme based on your company's maturity, calculating aid intensities, distinguishing a grant from a repayable tranche, and combining everything with the tax deduction and the social security rebate is a matter of strategy, not form-filling. Getting it right can multiply the return on every euro you invest in technology.
Want to know which forms of support your technology project can access and how to combine them with the tax deduction? Talk to our team and we will design a tailored innovation funding strategy with you.
For further reading, see also our general guide to innovation funding, R&D and M&A, the specific analysis of the R&D tax deduction applied to software development and, if you are considering corporate transactions, our article on M&A in tech companies.
Sources: CDTI (cdti.es); Neotec 2026 call (BOE-B-2026-10827); Zabala Innovation (zabala.es); Agencia Tributaria; Spanish Corporate Income Tax Law 27/2014, of 27 November (Articles 35 and 39); Royal Decree 475/2014 on social security contribution rebates for research staff; tecnociminnova.com/es.
